Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study)
Cephalalgia · 2025-04 · 45 (4)
DOI: 10.1177/03331024251335927 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cephalalgia, online erschienen am 23.04.2025. Verfasst von Fabrizio Vernieri und 21 weiteren Autor:innen. Beteiligte Einrichtung: Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy. Hauptthemen laut MEDLINE: Migraine Disorders. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Focusing on calcitonin gene-related peptide (CGRP) as a specific target has changed and improved migraine management. After the positive results of monoclonal antibodies directed to the CGRP pathway (anti-CGRP mAbs), randomized controlled trials also demonstrated the efficacy of gepants in migraine prevention. The present study aimed to assess the effectiveness of atogepant in preventing migraine after a 12-week treatment in clinical practice.
Methods
Adult patients with a clinical indication for atogepant 60 mg daily were screened for participation in this multicentric prospective observational cohort study. At baseline (T0) and after 12 weeks (T3) since the first atogepant administration, monthly migraine days (MMDs), monthly headache days (MHDs) and monthly acute medications (MAMs) were assessed. The co-primary endpoints were the changes in MMDs from T0 to T3 and the percentage of T3 Responders (those with a reduction of MMDs ≥50%, i.e. 50% response rate (RR)). At T0 and T3, we also collected the Headache Impact Test (HIT-6), the Migraine Disability Assessment (MIDAS) questionnaire, the Migraine Treatment Optimization Questionnaire-6 (mTOQ-6), the Migraine-Specific Quality-of-Life Questionnaire (MSQ), the 12-item Allodynia Symptom Checklist (ASC-12) and the Migraine Interictal Burden Scale (MIBS-4).
Results
One hundred and six patients (56/106 (52.8%) with chronic migraine (CM), 93/106 (87.7%) female, aged 50.6 ± 13.2 years) from 10 Italian centers completed the 12-week observation since the first atogepant tablet intake. From baseline to T3, a reduction of 6.9 MMDs (SD 9.7; p < 0.001) was achieved in the whole group and, specifically, of −4.9 (SD 6.6; p < 0.001) in episodic migraine (EM) and of −8.6 (SD 11.7; p < 0.001) in CM patients. Overall, 60/106 (56.6%) of patients were Responders (60.0% in the EM and 46.4% in the CM group). Non-Responders previously experienced more ineffective treatments than Responders with anti-CGRP mAbs (65.2% vs. 43.3%, respectively, p = 0.031) and with onabotulinumtoxinA (56.5% vs. 28.3%, p = 0.005), and presented more medication overuse at baseline (55.7% vs. 44.3%, p = 0.003). However, no baseline characteristics were significantly associated with the Responder status in the multiple regression analysis. For T0 to T3, MAMs, MIDAS, ASC-12 and mTOQ-6 reduced ( p ≤ 0.001 consistently), and MSQ role-function restriction increased ( p = 0.026), whereas HIT-6 and MIBS-4 did not change. Only seven subjects (7/106, 6.6%) dropped out of atogepant treatment: four for lack of effectiveness and three for adverse events or poor tolerability.
Conclusions
The STAR study demonstrates the effectiveness and tolerability of atogepant 60 mg at 12 weeks in a real-world setting. Previous ineffective anti-CGRP mAbs were not a relevant prognostic factor. Trial Registration The study was preregistered on clinicaltrial.gov, NCT06414044.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
- Neurology Unit, Università Campus Bio-Medico di Roma, Roma, Italy.
- Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico Di Modena, Modena, Italy.
- Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy.
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina, Italy.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
ORCID-Profile: Fabrizio Vernieri, Luigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis, Raffaele Ornello, Licia Grazzi, Danilo Antonio Montisano, Luisa Fofi, Gloria Vaghi, Simona Sacco, Claudia Altamura
Zitieren
APA
Vernieri, F., Iannone, L. F., Lo Castro, F., Sebastianelli, G., De Santis, F., Corrado, M., Marcosano, M., Ornello, R., Grazzi, L., Montisano, D. A., De Cesaris, F., Munafò, A., Fofi, L., Doretti, A., Vaghi, G., Pistoia, F., Ferrandi, D., Battistini, S., Sacco, S., …, & Italian Headache Registry (RICe) Study Group (2025). Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study). Cephalalgia, 45(4). https://doi.org/10.1177/03331024251335927
Vancouver
Vernieri F, Iannone LF, Lo Castro F, Sebastianelli G, De Santis F, Corrado M, et al. Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study). Cephalalgia. 2025;45(4). doi:10.1177/03331024251335927
BibTeX
@article{Vernieri2025,
author = {Vernieri, Fabrizio and Iannone, Luigi Francesco and Lo Castro, Flavia and Sebastianelli, Gabriele and De Santis, Federico and Corrado, Michele and Marcosano, Marilena and Ornello, Raffaele and Grazzi, Licia and Montisano, Danilo Antonio and De Cesaris, Francesco and Munafò, Antonio and Fofi, Luisa and Doretti, Alberto and Vaghi, Gloria and Pistoia, Francesca and Ferrandi, Delfina and Battistini, Stefania and Sacco, Simona and Guerzoni, Simona and Altamura, Claudia and Italian Headache Registry (RICe) Study Group, Italian Headache Registry (RICe) Study Group},
title = {Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study)},
journal = {Cephalalgia},
year = {2025},
volume = {45},
number = {4},
doi = {10.1177/03331024251335927}
}
EUVIMED